Summary
57 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $445.8M against $67.8M.
- Analysts expect revenue to grow by 39% this fiscal year.
- Out of every 100 USD of revenue, 18 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 39%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $1.58B.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $29.2 is 29% above today's price. 44% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Non-US 53%
- UNITED STATES 47%
Non-US brings in 53% of revenue.
Segments in detail